TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06045182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maitland mobilization
Description: Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maitland mobilization
Description: Participants in this group will be first given hot pack and TENS for 10 min. Then they will be given Maitland Mobilizations (10 oscillations total of 3 sets )with 10 sec rest in between. Mobilization will be Unilateral or central based on the patient condition and Intensity of Mobilizations increases as per patient tolerance in 2nd and 3rd session.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piriformis stretch
Description: Piriformis stretch will be given to this group. In first session piriformis stretch will be given for 10 sec with 10-second resting time in between with, 7 rep total of 1 set. For the 2nd and 3rd session repetitions will be increase to 8 and 10 respectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy
Description: Hot pack and TENS for 10 min
Study: NCT05589233

Intervention type: BIOLOGICAL
Intervention: Vaccionation eighter started or full course
Description: Vaccination against SARS-CoV-2 at any number of doses
Study: NCT04606316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Treatment of disease or injury by cutting, abrading, suturing, or otherwise physically changing body tissues and organs.
Study: NCT06094699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep friendly order set
Description: Every evening, the following orders (which comprise the sleep-friendly order set) will be input into the EMR:~Hold vital signs and neurological checks overnight Retime applicable medications outside of the nighttime window of 10pm-6am Retime daily lab draws outside of the nighttime window of 10pm-6am Order melatonin if no clinical contraindications Discontinue finger stick glucose measurements for patients with a stable blood glucose values Change DVT prophylaxis to enoxaparin for all clinically eligible patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient sleep menu
Description: Patients will be given a menu of non-pharmacological options that support sleep by improving comfort and reducing anxiety.
Study: NCT04987957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Classical Music, Turkish Classical Music, Turkish Folk Music and Sufi Music
Study: NCT04779476

Intervention type: OTHER
Intervention: Socket Dressing
Description: Following dental extraction immediately, the socket will be dressed with one of the materials tested

Intervention type: OTHER
Intervention: Socket Dressing
Description: Following dental extraction immediately, the socket will be dressed with one of the materials tested
Study: NCT05488327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All subjects will be treated with lenalidomide 5mg/day with a regular follow-up of 24 weeks.
Study: NCT05754736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametinib combined with bevacizumab
Description: Ametinib 110mg po qd bevacizumab 15mg/kg ivdrip q3w
Study: NCT06186089

Intervention type: DIETARY_SUPPLEMENT
Intervention: probiotics
Description: patients undergoing total gastrectomy take probiotics qd for 3 months
Study: NCT04828928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electromyogram
Description: Patients meeting the criteria will be seen in consultation with standardized interview and clinical examination. An electromyogram will be then carried out to check for the presence of neuropathy. Finally, for patients diagnosed with neuropathy, a biological check-up to look for another cause of neuropathy will be performed. In patients who already had an EMG as part of their medical follow-up, the examination will not be repeated if it strictly meets the conditions of the minimum protocol and if it was done within the year prior to inclusion. In patients who already had an identical biological assessment in the year prior to inclusion, the sample will not be taken.
Study: NCT06133231

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants
Description: Participants will take 2-4 capsules of EMP+ Advanced per day (max 8 capsules) for eight weeks.
Study: NCT06340269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEX-CD1 Dialysis
Description: MEX-CD1 is a hyper-chelating colloidal solution that can be added to the dialysate to be used in Slow low-volume continuous veno-venous hemodialysis. One treatment will last 3 hours and 20 minutes.~Patients enrolled are hospitalized in Intensive Care Unit.
Study: NCT05681923

Intervention type: OTHER
Intervention: Questionnaires
Description: Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.

Intervention type: OTHER
Intervention: Questionnaires
Description: Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.

Intervention type: OTHER
Intervention: Biospecimen collection
Description: urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta

Intervention type: OTHER
Intervention: Biospecimen collection
Description: urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta

Intervention type: OTHER
Intervention: Neurodevelopmental assessment visit
Description: High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals.

Intervention type: OTHER
Intervention: Neurodevelopmental assessment visit
Description: High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.~A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.~Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals.

Intervention type: OTHER
Intervention: DNA collection
Description: If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
Study: NCT05837221

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic sequencing
Description: Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic sequencing
Description: Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic sequencing
Description: Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metagenomic sequencing
Description: Shotgun metagenomic sequencing will characterize cancer-associated changes in microbial functional capacity and species/strain-level taxonomic profiles. Metagenomics will provide data on microbial functional capacity along with broader taxonomic classifications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic analysis
Description: Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic analysis
Description: Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic analysis
Description: Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolic analysis
Description: Metabolic analysis will be conducted using LC/MS-based metabolic analysis. A targeted approach will quantify a panel of 30 compounds including Trp pathway products while a non-targeted approach, when applied to both lipid and aqueous phase compounds, will profile relative changes in compounds that may influence host
Study: NCT06544330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNCAR-001
Description: SYNCAR-001 is an autologous CD19-targeted CAR-T with co-expression of hoRb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-009
Description: STK-009 is a human orthogonal IL-2 cytokine selective for SYNCAR-001 CAR-T cells expressing hoRb
Study: NCT06026605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX212A
Description: WTX212A infusion once every 21 days
Study: NCT05183035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemtuzumab Ozogamicin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Intravenous (IV) infusion or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous (IV) infusion or subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally via tablet or powder suspension
Study: NCT05837767

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: The primary site requiring palliative radiotherapy will receive conventional SBRT dosing of SBRT (or an alternate standard-of-care schedule).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Radiation Therapy
Description: A second metastatic site (GTV volume at least 100 cc) will receive elective palliation with a lattice RT pattern (LRT).
Study: NCT05369429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Wellbeing Guide
Description: The intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.
Study: NCT06547489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zelquistinel
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zelquistinel
Description: Zelquistinel is a positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
Study: NCT06045182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: Hot pack and TENS for 10 min
Study: NCT06086444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: Tranexamic Acid (10mg/kg), diluted in 100 ccs of normal saline. Administered intravenously at least 10 minutes before skin incision.
Study: NCT04862949

Intervention type: DRUG
Intervention: Atezolizumab plus bevacizumab
Description: Atezolizumab plus bevacizumab
Study: NCT05536492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRF
Description: EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALLOGRAFT
Description: EXTRACTION FOR SINGLE rooted tooth followed by augmentation with PRF + ALLOGRAFT
Study: NCT06079060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Nitrile Condom (61mm)
Description: 61mm width Synthetic Nitrile Condoms

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Latex Condom
Description: 61mm width Natural Rubber Latex Condom
Study: NCT05585229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted Psychotherapy
Description: Participants will complete a 8-week structured psychotherapeutic intervention involving administration of 25mg and 37.5mg PEX010 on two separate occasions.
Study: NCT05208086

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of monoclonal component
Description: Monoclonal component analysis by electrophoresis and immnuofixation on the urine sample from miction and 24h urine sample.
Study: NCT04923646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primer
Description: Mailed postcard notifying Veteran of upcoming FIT kit for annual CRC screening.
Study: NCT06055465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: * 4 cycles, each cycle lasting for 3 weeks~* 10mg/kg given every day 1 and day 8 each cycle~* IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: * 4 cycles, each cycle lasting for 3 weeks in Neoadjuvant phase; after surgery, 13 cycles, each cycle lasting for 3 weeks in Maintenance phase.~* 200mg fixed dose every day 1 each cycle~* IV infusion
Study: NCT06066905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide and azacitidine
Description: chidamide：10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.~azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.
Study: NCT04153838

Intervention type: OTHER
Intervention: Cognitive test administration
Description: Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
Study: NCT06524570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU-HT
Description: High-Intensify Focused Ultrasound Histotripsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI
Description: Ipilimumab and nivolumab
Study: NCT06306664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioptron
Description: Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.
Study: NCT05404919

Intervention type: DRUG
Group type: OTHER
Intervention: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
Description: Anti-hepatitis B medications
Study: NCT06306664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioptron
Description: Bioptron safely treats arthritis, neck \& back pain by stimulating blood circulation, reducing inflammation and relieving muscle spasms. For just ten minutes per day, our life-transforming technology offers the highest levels of pain relief by reaching deep into joints, muscles and ligaments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients will receive ice application+Exercises program designed for jumper knee
Study: NCT05685732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Description: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study: NCT05149040

Intervention type: OTHER
Intervention: survey Intensive care of very elderly: What do they wish for themselves?
Description: self-administered mailed survey

Intervention type: OTHER
Intervention: survey Intensive care of very elderly: What do they wish for themselves?
Description: self-administered mailed survey
Study: NCT04831203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: An egg-protein hydrolysate (NWT-03)
Description: As described in the experimental arm

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As described in the Control arm
Study: NCT05893407

Intervention type: DIAGNOSTIC_TEST
Intervention: Measuring contrast-enhanced ultrasound perfusion with phase inversion harmonic imaging
Description: Contrast-enhanced ultrasound perfusion imaging (PerCEUS) will be performed by a dedicated study team. The transcranial color duplex sonography will be performed with a 1-5 MHz dynamic sector array (S5-1) from a Philips Epiq 7 ultrasound machine (Philips Healthcare, Andover, MA). The field-of-view will be set to an imaging depth of 150 mm in a sector angle of 90°. The imaging plane will be then tilted to the diencephalic, in which the frontal horns of the side ventricles and the third ventricle serve as landmarks and where the anterior and posterior middle cerebral artery (MCA) territory and the basal ganglia (BG) as region of interest could be identified without artefacts from major vessels. High mechanical index bolus imaging will be performed from the sanest side of the head. Data acquisition of 45 seconds will be recorded immediately after the beginning of the contrast ultrasound imaging, using a mechanical index (MI) setting of 1.1 and a frame rate of 33 Hz.
Study: NCT04709406

Intervention type: DRUG
Intervention: deep neuromuscular blockade in bariatric surgery
Description: obese patients who underwent bariatric surgery
Study: NCT06359886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: B-Lynch Transverse Compression Suture
Description: closure of uterine and utero ovarian arteries bilaterally with one suture
Study: NCT06084065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CART-I Plus
Description: Photoplethysmography based ring-type blood pressure measurement device
Study: NCT05068063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
Study: NCT05685004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TVI-Brain-1
Description: Attenuated autologous cancer cells and activated autologous blood-derived t cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Surgery for tumor removal or debulking to minimize tumor burden

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Surgery for tumor removal or debulking to minimize tumor burden

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conformal radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday through Friday) over a period of six weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: All Subjects receive 75 mg/m2 of temozolomide daily beginning on the first day of radiotherapy and continuing until the completion of radiotherapy. Standard of care Subjects will also receive adjuvant temozolomide .
Study: NCT06211075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia with Motivational Interviewing
Description: This intervention implements elements of Cognitive Behavioural Therapy for Insomnia with motivational interview techniques incorporated into the intervention, aiming to build long-lasting motivation, better rapport with the patients and self-efficacy to increase engagement rate despite its remotely delivered format. The whole intervention is delivered online.